loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of All Manufacturers & Suppliers for 213217 Licensing, EU CTD Dossiers, Marketing Authorizations, Finished Dosage Formulations listed on PharmaCompass.com

    Client Virtual Booth
    Menu

    BeiGene

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 ZANUBRUTINIB (1)

    filter

    01 BEIGENE (1)

    filter

    01 CAPSULE;ORAL (1)

    filter

    01 80MG (1)

    filter

    01 USA (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us
    Contact Supplier
      Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
      Post an Enquiry Post an Enquiry
      Flag China
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Zanubrutinib

      PDF Supplier PDF
      URL Supplier Web Content
      CAPSULE;ORAL
      80MG
      BRUKINSA
      USA
      213217
      2019-11-14
      RX
      ASK
      US
      PHARMACOMPASS
      Upload
      your Marketing & Sales content

      Looking for CTD TGA MCC DOSSIER APPLICATION 213217

      Looking for CTD TGA MCC DOSSIER APPLICATION 213217 1

      19

      BeiGene, based in China, is a pharmaceutical company.

      One of their notable products is ZANUBRUTINIB, with a corresponding application number 213217 and regulatory information .

      proudly manufactured in the

      approval since 2019-11-14

      BeiGene's BRUKINSA CAPSULE;ORAL, medication with 80MG of ZANUBRUTINIB.

      Post Enquiry
      POST ENQUIRY